357 related articles for article (PubMed ID: 18674928)
21. Evaluation of eco-friendly zwitterionic detergents for enveloped virus inactivation.
Conley L; Tao Y; Henry A; Koepf E; Cecchini D; Pieracci J; Ghose S
Biotechnol Bioeng; 2017 Apr; 114(4):813-820. PubMed ID: 27800626
[TBL] [Abstract][Full Text] [Related]
22. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.
Dichtelmüller H; Rudnick D; Breuer B; Kotitschke R; Kloft M; Darling A; Watson E; Flehmig B; Lawson S; Frösner G
Biologicals; 1996 Jun; 24(2):125-30. PubMed ID: 8889059
[TBL] [Abstract][Full Text] [Related]
23. Inactivation of influenza A virus H1N1 by disinfection process.
Jeong EK; Bae JE; Kim IS
Am J Infect Control; 2010 Jun; 38(5):354-60. PubMed ID: 20430477
[TBL] [Abstract][Full Text] [Related]
24. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
[TBL] [Abstract][Full Text] [Related]
26. Virus inactivation by protein denaturants used in affinity chromatography.
Roberts PL; Lloyd D
Biologicals; 2007 Oct; 35(4):343-7. PubMed ID: 17517521
[TBL] [Abstract][Full Text] [Related]
27. Insights into virus inactivation by polysorbate 80 in the absence of solvent.
Chen D; Luo W; Hoffman J; Huang L; Sandefur S; Hall T; Murphy M; O'Donnell S
Biotechnol Prog; 2020 May; 36(3):e2953. PubMed ID: 31846227
[TBL] [Abstract][Full Text] [Related]
28. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
Hilfenhaus J; Nowak T
Vox Sang; 1994; 67 Suppl 1():62-6. PubMed ID: 8091740
[TBL] [Abstract][Full Text] [Related]
30. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
31. Butyroyl-arginine as a potent virus inactivation agent.
Katsuyama Y; Yamasaki H; Tsujimoto K; Koyama AH; Ejima D; Arakawa T
Int J Pharm; 2008 Sep; 361(1-2):92-8. PubMed ID: 18617337
[TBL] [Abstract][Full Text] [Related]
32. "In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate.
Arrighi S; Rossi R; Borri MG; Lesnikov V; Lesnikova M; Franco E; Divizia M; De Santis ME; Bucci E
Thromb Haemost; 1995 Sep; 74(3):868-73. PubMed ID: 8571312
[TBL] [Abstract][Full Text] [Related]
33. A solvent I detergent treated, pasteurised and highly purified factor VIII concentrate.
Schwinn H; Stadler M; Josic D; Bal F; Gehringer W; Nur I; Schütz R
Arzneimittelforschung; 1994 Feb; 44(2):188-91. PubMed ID: 8147954
[TBL] [Abstract][Full Text] [Related]
34. Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems.
Burnouf T; Caron C; Radosevich M; Goubran HA; Goudemand J; El-Ekiaby M
Haemophilia; 2008 Sep; 14(5):956-62. PubMed ID: 18565126
[TBL] [Abstract][Full Text] [Related]
35. Identification and characterization of a Triton X-100 replacement for virus inactivation.
Luo W; Hickman D; Keykhosravani M; Wilson J; Fink J; Huang L; Chen D; O'Donnell S
Biotechnol Prog; 2020 Nov; 36(6):e3036. PubMed ID: 32533632
[TBL] [Abstract][Full Text] [Related]
36. Solvent/detergent treatment of platelet concentrates enhances the release of growth factors.
Burnouf T; Tseng YH; Kuo YP; Su CY
Transfusion; 2008 Jun; 48(6):1090-8. PubMed ID: 18373502
[TBL] [Abstract][Full Text] [Related]
37. Extraction of Triton X-100 and its determination in virus-inactivated human plasma by the solvent--detergent method.
Strancar A; Raspor P; Schwinn H; Schütz R; Josic D
J Chromatogr A; 1994 Jan; 658(2):475-81. PubMed ID: 8118553
[TBL] [Abstract][Full Text] [Related]
38. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins.
Brorson K; Krejci S; Lee K; Hamilton E; Stein K; Xu Y
Biotechnol Bioeng; 2003 May; 82(3):321-9. PubMed ID: 12599259
[TBL] [Abstract][Full Text] [Related]
39. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions.
Roberts PL; Feldman P; Crombie D; Walker C; Lowery K
Biologicals; 2010 Mar; 38(2):303-10. PubMed ID: 20089418
[TBL] [Abstract][Full Text] [Related]
40. [Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems].
Burnouf T; Goubran HA; Radosevich M; El-Ekiaby M
Transfus Clin Biol; 2008 Jun; 15(3):129-34. PubMed ID: 18538608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
